ImmunityBio (IBRX) is down -23.0%, or -$2.16 to $7.24.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio receives FDA warning letter on Anktiva promotion
- ImmunityBio call volume above normal and directionally bullish
- ImmunityBio announces approval in Macau for Anktiva
- Mixed options sentiment in ImmunityBio with shares up 3.53%
- Buy Rating on ANKTIVA: NCCN Guideline Expansion, Off‑Label Upside, and DCF‑Backed Risk‑Reward in BCG‑Unresponsive NMIBC